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Abstract
Hookworms infect more people than HIV and malaria combined, predominantly in third world countries. Treatment of
infection with chemotherapy can have limited efficacy and re-infections after treatment are common. Heavy infection often
leads to debilitating diseases. All these factors suggest an urgent need for development of vaccine. In an attempt to
develop a vaccine targeting the major human hookworm, Necator americanus, a B-cell peptide epitope was chosen from the
apical enzyme in the hemoglobin digestion cascade, the aspartic protease Na-APR-1. The A291Y alpha helical epitope is
known to induce neutralizing antibodies that inhibit the enzymatic activity of Na-APR-1, thus reducing the capacity for
hookworms to digest hemoglobin and obtain nutrients. A291Y was engineered such that it was flanked on both termini by
a coil-promoting sequence to maintain native conformation, and subsequently incorporated into a Lipid Core Peptide (LCP)
self-adjuvanting system. While A291Y alone or the chimeric epitope with or without Freund’s adjuvants induced negligible
IgG responses, the LCP construct incorporating the chimeric peptide induced a strong IgG response in mice. Antibodies
produced were able to bind to and completely inhibit the enzymatic activity of Na-APR-1. The results presented show that
the new chimeric LCP construct can induce effective enzyme-neutralising antibodies in mice, without the help of any
additional toxic adjuvants. This approach offers promise for the development of vaccines against helminth parasites of
humans and their livestock and companion animals.
Citation: Skwarczynski M, Dougall AM, Khoshnejad M, Chandrudu S, Pearson MS, et al. (2012) Peptide-Based Subunit Vaccine against Hookworm Infection. PLoS
ONE 7(10): e46870. doi:10.1371/journal.pone.0046870
Editor: David Joseph Diemert, The George Washington University Medical Center, United States of America
Received June 20, 2012; Accepted September 6, 2012; Published October 3, 2012
Copyright:  2012 Skwarczynski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Health and Medical Research Council of Australia (NHMRC Programme Grant 496600), http://www.nhmrc.gov.
au/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors also thank Thalia
Guerin for her correction of this manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: alex.loukas@jcu.edu.au (AL); i.toth@uq.edu.au (IT)
. These authors contributed equally to this work.
Introduction
Hookworm infection causes one of the world’s most debilitating
neglected tropical diseases. The human hookworm (Necator
americanus) infects over 700 million people worldwide, predomi-
nantly in indigent rural and tropical regions [1]. Chronic infection
results in long-term pathological consequences primarily due to
ongoing intestinal blood loss resulting from the feeding activities of
these hematophagous parasites. Heavy infection leads to iron-
deficiency anemia and can manifest as impaired neurological and
intellectual functioning in children, reduced work capacity in
adults, and severe adverse outcomes in pregnancy [2]. Those most
vulnerable to the harmful effects of hookworm include children
and pregnant women, who are unable to tolerate the chronic
blood loss and iron deficiency anemia due to their lower iron
reserves [3]. These factors have significant influence on current
and future productivity and economic well being of infected
populations. Benzimidazole drugs are commonly used for the
treatment and eliminate adult parasites. However, chemotherapy
has limited efficacy and reinfection after treatment is common
[4,5]. The problems with drug effectiveness and the looming
threat of drug resistance suggest that alternatives to mass drug
administration are urgently needed. Development of a vaccine
that would prevent the acquisition of moderate or heavy intensity
hookworm infection would be a major advance in reducing the
morbidity caused by this parasite [6,7]. Currently, there is no
human hookworm vaccine on the market or in advanced clinical
trials.
Hookworms obtain their nourishment primarily by ingesting
blood and digesting the hemoglobin and serum proteins released
from lysed erythrocytes. Na-APR-1 is a cathepsin D aspartic
protease derived from the gut of adult N. americanus where it
initiates the hemoglobin digestive cascade [8,9]. Therefore,
blocking the catalytic activity of Na-APR-1 via the induction of
neutralizing antibodies should result in starving and ultimately
killing of the parasite. Indeed, it was demonstrated that APR-1
could be used as an efficacious hookworm vaccine antigen against
A. caninum in dogs. Vaccination with the recombinant N. americanus
or A. caninum enzymes induced antibodies that bound to the gut of
the parasite and neutralized the enzymatic activity of the protease
in vitro. When vaccinated dogs were then challenged with
hookworm larvae they had significantly diminished adult parasite
burdens and a reduction in blood loss was observed [8,10].
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However, production of APR-1 at a commercial scale has proven
to be challenging due to protein aggregation and low manufactur-
ing yield obtained from eukaryotic expression systems. Previously,
the immunogenic peptide epitope from N. americanus APR-1
(A291Y, AGPKAQVEAIQKY) was shown to induce the pro-
duction of neutralizing antibodies in vivo. These antibodies were
able to inhibit enzymatic activity of APR-1 against synthetic
peptide and natural protein substrates [11].
Peptide antigens are not immunogenic by themselves and
require appropriate delivery systems and strong, often toxic,
adjuvants to stimulate desired immune responses [12]. For
example, in the above-mentioned study the use of toxic complete
Freund’s adjuvant composed of inactivated and dried mycobac-
teria was necessary to stimulate immune responses against the
A291Y epitope. To avoid this problem, lipidation of peptides
emerged as a promising strategy for delivery of peptide subunit
vaccines. The self-adjuvanting Lipid Core Peptide (LCP) delivery
system has a demonstrated ability to induce strong immune
responses against the incorporated peptide-epitopes without the
help of external adjuvants, and is considered to be a capable
platform for development of human vaccines [13,14].
In this paper, we have designed, synthesized and characterized
a short series of A291Y conjugates. We have used the coil-
promoting sequence from the yeast GCN4 protein to induce
native helical A291Y epitope conformation [11,13,15,16]. Sub-
sequently, chimeric and parent A291Y epitopes were incorporated
into the LCP delivery system. The various LCP constructs induced
variable IgG responses in mice, nonetheless these antibodies were
able to bind to and completely inhibit the enzymatic activity of Na-
APR-1. The results presented show that the new chimeric epitope
can be presented as an LCP construct to induce an effective
enzyme-neutralizing response without the help of any additional
adjuvants and delivery systems. This approach offers promise for
the development of vaccines against helminth parasites of humans
and their livestock and companion animals.
Materials and Methods
I. Materials
Protected L-amino acids were obtained from Novabiochem
(Laufelfingen, Switzerland) and Mimotopes (Melbourne, Austra-
lia). pMBHA resin was purchased from Peptides International Inc.
(Kentucky, USA). 1-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylur-
onium hexafluorophosphate (HBTU) was purchased from Mimo-
topes. HPLC grade acetonitrile and N,N-dimethylformamide were
obtained from Ajax Finechem (Sydney, Australia). Trifluoroacetic
acid (TFA) was obtained from Merck (Kilsyth, Australia). All other
reagents were obtained from Sigma-Aldrich (Castle Hill, NSW,
Australia). Microwave assisted Fmoc SPPS was carried out by
using a SPS mode on CEM Discovery reactor (CME Corporation,
Matthews, NC, USA). An AKel-F HF apparatus (Peptide Institute,
Osaka, Japan) was used for HF cleavage. ESI-MS was performed
on a Perkin-Elmer-Sciex API3000 instrument with Analyst 1.4
software (Applied Biosystems/MDS Sciex, Toronto, Canada).
Analytical RP-HPLC was performed on an Agilent instrument
with a 1.0 mL/min flow rate and detection at 214 nm. Separation
was achieved by running gradient mode of 0–100% solvent B over
40 min with solvent A (0.1% TFA/H2O) and two kind of solvent
B (B1:90% MeCN/0.1% TFA/H2O or B2:90% MeOH/0.1%
TFA/H2O) on either a Vydac analytical C4 column (214TP54;
10 mm, 4.66250 mm) or a Vydac analytical C18 column
(218TP54; 10 mm, 4.66250 mm). Purification was carried out
by preparative RP-HPLC using a Waters Delta 600 system with
a 10.0 mL/min flow rate. Compounds were detected at 230 nm.
Separations were performed with solvent A and solvent B1 on
either a Vydac preparative C4 column (214TP1022; 10 mm,
226250 mm) or a Vydac preparative C18 column (218TP1022;
10 mm, 226250 mm). CD spectra were measured on a JASCO J-
710 spectropolarimeter (Tokyo, Japan) using a quartz cuvette of
1 mm path length at 23uC. The CD spectra were measured in
water with trifluoroethanol (TFE) at concentration of 10% (v/v).
II. Synthesis of Peptide Epitopes and LCPs
Peptides 1 and 2 (Figure 1) were synthesized using manual
SPPS at 0.1 mmol scale with pMBHA (0.45 mmol NH2/g) resin.
The synthesis was carried out as previously reported [17,18,19].
Shortly thereafter, Boc-deprotection was performed with neat
TFA (261 min), followed by a 1 min DMF flow wash, and
a 30 min coupling with pre-activated Boc-protected amino acid (1
hour in the case of lipoamino acid (2-(R/S)-[(tert-butoxycarbony-
l)amino]-dodecanoic acid)) [17,20]. Amino acid pre-activation was
achieved by dissolving amino acids (4.2 equiv.) in 0.5 M HBTU/
DMF solution (4.0 equiv.), and DIPEA (6.2 equiv.). Activation
proceeded for 2–3 min, except for lipoamino acids which were
pre-activated for 5–10 min. Double coupling was performed for all
amino acids.
Peptide 1. Yield: 33%. Molecular Weight: 1443.7.
[M+1H+]1+ m/z 1444.7 (calc. 1444.77), [M+2H+]2+ m/z 722.8
(calc. 722.89). tR = 13.79 (0–100% Solvent B1, 30 min; C18),
tR = 21.37 (0–100% Solvent B2, 30 min; C18).
Peptide 2. Yield: 28%. Molecular Weight: 3210.7.
[M+3H+]3+ m/z 1071.8 (calc. 1071.25), [M+4H+]4+ m/z 803.9
(calc. 803.69). tR = 13.8 (0–100% Solvent B1, 30 min; C18),
tR = 21.33 (0–100% Solvent B2, 30 min; C18).
LCP-1 and LCP-2 (Figure 1) were synthesized using micro-
wave-assisted SPPS at 0.05 mmol scale with pMBHA (0.45 mmol
NH2/g) resin. Microwave-assisted SPPS was applied with two five
minute microwave-assisted couplings (SPS mode, power 20 W,
temperature 70uC, DT =1uC) for each amino acids (4.2 equiv.)
using HBTU (4.0 equiv.) and DIPEA (6.2 equiv.) [21]. The
lipoamino acids were coupled in the same manner as regular
amino acids but with extended (5–10 mins) HBTU/DIPEA pre-
activation. N-terminal acetylation, TFA-assisted Boc cleavage and
final cleavage from resin was performed as reported previously
[17].
LCP-1. Yield: 46%. Molecular Weight: 6814.1. [M+5H+]5+
m/z 1364.3 (calc. 1363.81), [M+6H+]6+ m/z 1136.8 (calc.
1136.67). tR = 20.7, 20.96, 21.19, 21.66 (0–100% Solvent B1,
30 min; C4), tR = 29.82, 30.39, 30.61, 31.03 (0–100% Solvent B2,
30 min; C4).
LCP-2. Yield: 38%. Molecular Weight: 13886.1.
[M+11H+]11+ m/z 1263.1 (calc. 1263.38), [M+12H+]12+ m/z
1158.4 (calc. 1158.11). tR = 18.39, 18.61 (0–100% Solvent B1,
30 min; C4), tR = 27.20 (0–100% Solvent B2, 30 min; C4).
II. Toxicological Evaluation
Hemolytic assay. Using a standard hemolytic assay, the
capacity of LCP compounds (LCP-1 and LCP-2) to induce
hemolysis was examined (Figure 2). Blood was collected from
a healthy human volunteer with written informed consent
(protocol approved by the University of Queensland Ethics
Committee, approval number 2009000661). The toxicity of the
compounds was tested in three concentrations, (10, 50, and
100 mM) and incubated at 37uC for one hour. SDS was used as
the positive control and PBS as negative control. After one hour,
the plate was centrifuged at 7506 g for 15 min and 75 mL of
supernatant per well was transferred to a new 96 well plate. The
absorbance at 540 nm was recorded by UV spectrometer. The
Peptide-Based Vaccine against Hookworm
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data was calculated according to a standard formula:
%Hemolysis~ A540{minA540ð Þ= maxA540{minA540ð Þ½ |100%
where:
N -A540 is the average absorption of compound at 540 nm
N -minA540 is the average absorption of PBS
N -maxA540 is the average absorption of SDS.
MTT assay. The toxicity of the compounds (1–4) was
examined by MTT assay (Figure 2). The Caco-2 cells were
cultivated in a flask with DMEM (Dulbecco’s Modified Eagle
Medium) to reach 80% confluence. The cells were split into a 96
well plate (100 mL of cells per well) prior to the MTT test (to let the
cells adhere to on the surface). The compounds 1–4 were prepared
in three concentrations of 10, 50, and 100 mM in PBS. The culture
medium was removed and 100 mL of the compound solutions
were added to each well. The cells were incubated for 24 hours.
After the incubation, the solutions were removed and 20 mL of
MTT followed by 80 mL of DMEM medium was added to each
well. The plates were incubated for 4 hours, centrifuged at 7506g
for 5 mins, and the supernatant discarded. Fifty microliters of
DMSO was added to each well to dissolve the purple crystals. The
UV absorbance readings were taken at 570 nm wavelength. PBS
was used as a blank and SDS, 100% as a negative control. The
data was calculated according to a standard formula:
%Viability~ A540ð Þ= maxA540ð Þ½ |100%
where:
– A540 is the average absorption of compound at 540 nm
– maxA540 is the average absorption of DMEM (positive control).
III. Intraperitoneal Immunization of Mice with Constructs
Groups of four female BALB/c mice (4–6 weeks old) were
intraperitoneally injected with 30 mg of peptide 1+Fruend’s
adjuvants, peptide 2+Fruend’s adjuvants, LCP-1 or LCP-2 in
200 mL of PBS. All animal protocols used were approved by the
James Cook University Ethics Committee (A1484) in accordance
with National Health and Medical Research Council (NHMRC)
of Australia guidelines. For the Fruend’s adjuvants groups,
peptides 1 and 2, 100 mL (30 mg) of construct was mixed with
an equal volumes of Freund’s complete adjuvant (CFA) for the first
immunization and incomplete adjuvant for the subsequent
immunizations (Sigma). Mice were injected 4 times on days 0,
21, 33, and 43. Mice were euthanized on day 70 and the blood
collected via cardiac puncture. Sera were separated from clotted
blood by centrifugation at 3 000 rpm for 10 min.
In a second experiment, a total of five female BALB/c mice
were immunised with 60 mg per immunization of LCP-2 on days
0, 21, 32, and 35. On day 42 mice were euthanized and the sera
collected as above.
IV. ELISA
Antibody responses to the constructs were measured by ELISA.
Peptides or LCPs were coated on 96 well flat bottom ELISA plates
(BD) at a concentration of 5 mg/mL in 50 mM sodium carbonate
buffer at pH 9.6 and incubated overnight at 4uC. Non-reactive
sites were blocked with 3% bovine serum albumin in PBS/0.05%
Tween 20 (Sigma) for 1 hr at RT. Individual mouse sera were
added in duplicate using 10-fold serial dilutions to plates that were
coated with the respective immunogens. Total IgG binding was
detected using 1:2000 sheep anti-mouse IgG (H&L) conjugated to
horseradish peroxidase (Chemicon). Bound anti-mouse IgG was
detected using TMB single solution (Invitrogen). Plates were
measured at 655 nm on a POLARstar Omega microplate reader (BMG
Labtek). Absorbance was measured at 655 nm and corrected for
background using wells that received sera (1:100) in the absence of
peptide or LCP bound to the plate.
Figure 1. The structure of peptide epitopes (1, 2) and LCP constructs (LCP-1 and LCP-2). Peptide epitope 2 retains native epitope
sequence 1 (regular fonts) flanked by helicity inducing sequence from GCN4 protein (italic fonts).
doi:10.1371/journal.pone.0046870.g001
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V. Enzyme Neutralisation Assay
The IgG from the two highest responding mice (experiment 2)
were bound to protein G sepharose (Millipore) and eluted as
previously described [8,11]. After purification, IgG was concen-
trated and buffer exchanged into PBS using NanosepH centrifugal
devices (Pall) as per the manufacturer’s protocol. Yeast derived
recombinant of Na-APR-1 (60 ng) (kindly provided by Dr Bin
Zhan, George Washington University) was incubated with 2.5 and
1.25 mg of purified IgG in 50 mmol/L sodium acetate. Reactions
were performed in black 384 well plates (Greiner Bio One) in
50 ml; the substrate 7-methoxycoumarin-4-acetyl-
GKPILFFRLK(DNP)-d-Arg-amide (MoCAc-GKPILFFRLK)
(Sigma) was added to a final concentration of 1.0 mmol/L, and
the fluorescence generated (relative to substrate in buffer alone) by
substrate hydrolysis was measured as described [8] using
a POLARstar Omega microplate reader. Inhibition of enzymatic
activity was analysed as a percentage of the fluorescence generated
from an equivalent reaction containing equivalent amounts of
control IgG (Millipore) at 2.5 mg and 1.25 mg.
Results
I. Synthesis and Characterization
All compounds were synthesized using the stepwise Boc-SPPS
method in a similar manner to that described previously [17]. The
peptide epitopes and the tetra-branched LCP constructs were
obtained in highly pure form without difficulties. The CD spectra
were measured in water with trifluoroethanol (TFE) because this
solvent is known to stabilize the a-helical structure in peptides and
is often used to induce the native structure of protein fragments
[22,23,24]. According to CD analysis peptide epitopes showed
random coil rather than helical conformation with the minimum
observed at 199 nm and 201 nm for peptides 1 and 2,
respectively, while LCP core alone clearly did not form helical
structure (Figure 3). In contrast, LCP-1 and LCP-2 showed
Figure 2. Toxicity of lipid core peptides LCP-1and LCP-2. (a) Haemolytic potential of lipid core peptides (LCP) was measured by comparing the
absorbance (540 nm) of blood samples incubated with the LCP vaccine candidates with that of samples incubated with a positive control (SDS, 100%
haemolysis) and a negative control (PBS, 0%). Mean and SD of triplicates samples shown. (b) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide cell viability assays in triplicate were performed on the Caco-2 cell line with varying concentrations of compounds (10–100 mM).
doi:10.1371/journal.pone.0046870.g002
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helical conformation, with double minima at 207 nm, 219 nm and
206 nm, 220 nm.
II. Toxicological Evaluation
Basic toxicological evaluation of all compounds was performed
using MTT and haemolytic assays (Figure 2). It was clearly
demonstrated that all compounds were non-toxic to Caco-2 cells.
Lipophilic compounds, LCP-1 and LCP-2 were also assessed for
toxicity to red blood cells, and were shown to be non-haemolytic,
even at high concentrations (100 mM).
III. Antibody Binding and Neutralization of Recombinant
Na-APR-1
Mice that were immunized with peptide 1 with Freund’s
adjuvant did not induce a detectable IgG response in any mice.
Peptide 2 did not induce an IgG response alone but did induce
a weak IgG response when administered with adjuvant. LCP-1
(A291Y-LCP) induced a very weak IgG response that was barely
detectable, however LCP-2 (A291Y-GCN4-LCP) induced a stron-
ger IgG response but the titer was variable between individual
mice (Figure 4a). We repeated the vaccination experiment with
LCP-2 (experiment 2) this time using 60 mg of LCP-4 in an
attempt to improve the consistency and titer of the antibody
response (Figure 4b). Increasing the quantity of LCP-2 for
immunization resulted in a more consistent antibody response
between mice and higher titer responses.
IgG was purified from the two highest responding mice
(Figure 4b) that received the 60 mg dose of LCP-2 and used in
an Na-APR-1 enzymatic neutralization assay. IgG (2.5 mg) from
both mice inhibited the ability of APR-1 to digest a fluorescent
peptide substrate by 92–100% compared to control IgGs. The
inhibition is dose-dependent (Table 1) as described previously with
polyclonal and monoclonal IgGs from mice immunized with
recombinant Na-APR-1 [8,11].
Discussion
In our attempts to develop a human hookworm vaccine we
identified a number of antigens that showed promise in animal
models [6]. One of the lead antigens derived from the blood-
feeding adult stage of the parasite was Na-APR-1 [8,10]. There are
numerous obstacles facing the production and safe use of a vaccine
based on an active protease, so we identified an epitope from Na-
APR-1, A291Y, that was capable of inducing antibodies that
neutralized the catalytic activity of the recombinant enzyme [11].
Here we describe a self-adjuvanting approach to produce A291Y
fused to GCN4 and LCP, and show that antibodies generated to
the construct can neutralize the enzymatic activity of the native
enzyme, highlighting the utility of this approach for the de-
velopment of vaccines for neglected tropical diseases of humans.
The A291Y epitope was incorporated into the LCP system,
previously shown to stimulate B-cell immune response by
activation of dendritic cells via TLR-2 [25,26]. In prior studies,
we often observed difficulties in the synthesis and purification of
branched LCP constructs and the use of conjugation techniques
was necessary [18,27,28,29]. In contrast, herein simple stepwise
SPPS was applied for synthesis of all four compounds at high
purity. The proper conformation of peptide epitopes is crucial for
production of desired B-cell responses, thus we incorporated the
A291Y epitope (AGPKAQVEAIQKY, 1) in a coil-promoting
sequence from the yeast GCN4 protein using a standard technique
[15,24] to induce native a-helical conformation of the A291Y
epitope. Induction of helicity was not significant in the case of
chimeric peptide 2. However, when epitopes 1 and 2 were
incorporated into LCP system, both (LCP-1 and LCP-2) adopted
more helical than random conformation (Figure 3). This was in
agreement with our previous observation in the case of Group A
Streptococcus vaccine candidates [16,24,28]. Not surprisingly, LCP-1
exhibited a-helical properties despite this conjugate not containing
GCN4 flanking sequences. Induction of a-helicity of peptides due
to their conjugation to dendritic LCP core was previously reported
[28]. Similarly, helicity was also induced in peptides conjugated to
other dendrimers, presumably due to dense packing of peptide
epitopes in such structures [16]. LCP-1 and LCP-2 have
amphiphilic properties (surfactant-like), therefore there was a risk
that such compounds could be toxic to red blood cells. Using
a standard haemolytic assay, the capacity of LCP compounds to
induce haemolysis was examined and it was clearly demonstrated
Figure 3. CD spectra of peptides 1, 2, LCP-1 and LCP-2 in the presence of 10% of TFE. Spectra were acquired at 1 nm intervals from
260 nm to 190 nm, were the average of 3 individual scan and are reported in units of mean residue ellipticity [h].
doi:10.1371/journal.pone.0046870.g003
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that these compounds were not haemolytic even at high
concentration (Figure 2a). The preliminary toxicological studies
were performed with Caco-2 cells using an MTT assay (Figure 2b).
These human intestinal cells are often used to model toxicity of
compounds in vivo [30,31,32,33]. No considerable toxicity was
observed for any of the tested compounds.
In two separate experiments, LCP-2 induced inconsistent
antibody responses in BALB/c mice, characterized by strong
antibody responses in some mice and weak responses in others
(Figure 4). Similar variability in responses was reported for
immunization of mice with an LCP (J8) derived from a Group A
Streptococcus vaccine candidate [34]. Despite the inconsistency in
antibody responses, purified IgG directed against LCP-2 neutral-
ized the enzymatic activity of Na-APR-1, the primary goal of this
study (Table 1). The ratio of antibody to protease required to
neutralize the enzymatic activity was comparable to that obtained
with anti-A291Y neutralizing monoclonal antibodies [11].
An ultimate human hookworm vaccine is likely to require at
least two antigens, ideally from different developmental stages such
as the infective third-stage larva (L3) and the adult worm, to
achieve maximum efficacy [7]. Na-APR-1 is an ideal candidate
antigen from the adult stage parasite, however it is not abundantly
expressed in the L3. Antigens secreted by L3, such as Na-ASP-2
protect animals against heavy hookworm infections in pre-clinical
studies in animals [35], but this antigen elicited an atopic response
when administered to people in a hookworm-endemic area due to
circulating IgE induced by natural exposure to hookworms [36].
Epitopes were identified in Na-ASP-2 that were unique to IgG and
not IgE, implying that a peptide-based LCP vaccination strategy
focusing on IgG-specific epitopes is a logical approach to
developing human helminth vaccines. Such an approach might
also integrate multiple epitopes from distinct antigens into the one
LCP construct [27,34,37], as well as incorporation of universal T-
helper epitopes [38,39,40] to improve consistency in antibody
responses and to target outbred human populations. Overall, this
work provides the first rational basis for development of the
peptide-based vaccine against hookworm infection.
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